Valuation: Virbac

Market Cap 2.82B 3.17B 2.61B 2.38B 4.49B 302B 4.57B 31.46B 12.34B 157B 11.91B 11.66B 502B P/E 2026 *
16.3x
P/E 2027 * 14.7x
Enterprise Value 2.95B 3.31B 2.73B 2.49B 4.68B 315B 4.77B 32.82B 12.87B 164B 12.43B 12.16B 523B EV / Sales 2026 *
1.9x
EV / Sales 2027 * 1.75x
Free-Float
49.03%
Yield 2026 *
0.53%
Yield 2027 * 0.63%
1 day+0.15%
1 week+6.81%
Current month+8.19%
1 month+6.98%
3 months+5.31%
6 months-6.52%
Current year-5.73%
1 week 316
Extreme 316
339.5
1 month 297
Extreme 297
339.5
Current year 297
Extreme 297
389.5
1 year 297
Extreme 297
389.5
3 years 249.7
Extreme 249.7
400
5 years 215
Extreme 215
448.5
10 years 102.1
Extreme 102.1
448.5
Manager TitleAgeSince
Chief Executive Officer 46 31/08/2025
Chief Executive Officer 50 26/09/2024
Chief Operating Officer 64 31/12/2021
Director TitleAgeSince
Chairman 61 31/03/2006
Director/Board Member 68 27/07/2010
Director/Board Member 65 04/09/2017
Date Insider Type Main position Quantity % Market Cap. Importance
22/04/24 Sell

Chief Executive Officer

810 0.0096%
22/04/24 Sell

Chief Executive Officer

140 0.0017%
22/04/24 Sell

Chief Executive Officer

1,688 0.0200%
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%+6.81%+9.42%+30.37% 3.16B
+0.43%+7.48%+52.08%+106.34% 1,116B
+0.90%-0.36%+33.68%+62.93% 610B
+0.71%+4.77%+26.17%+92.90% 501B
+0.52%+2.51%+73.52%+40.32% 358B
-0.13%+7.51%+33.47%+48.68% 366B
-0.95%+5.93%+19.86%+42.48% 288B
-1.98%+4.66%-1.57%+13.41% 261B
-0.35%+6.15%+45.46%+52.23% 235B
-0.75%+6.18%+32.03%+101.15% 195B
Average -0.23%+5.41%+32.41%+59.08% 393.29B
Weighted average by Cap. -0.18%+4.93%+38.80%+72.12%

Financials

2026 *2027 *
Net sales 1.55B 1.74B 1.44B 1.31B 2.46B 166B 2.51B 17.28B 6.78B 86.32B 6.54B 6.4B 275B 1.64B 1.85B 1.52B 1.39B 2.61B 176B 2.66B 18.31B 7.18B 91.5B 6.93B 6.79B 292B
Net income 174M 196M 161M 147M 277M 18.63B 282M 1.94B 762M 9.71B 736M 720M 30.98B 194M 218M 179M 163M 308M 20.68B 313M 2.16B 846M 10.78B 817M 800M 34.4B
Net Debt 122M 138M 113M 103M 194M 13.07B 198M 1.36B 535M 6.81B 516M 505M 21.74B 44.72M 50.26M 41.39M 37.71M 71.05M 4.77B 72.32M 498M 195M 2.49B 189M 185M 7.94B
Projected Income Statement - Annual - Virbac
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Date Price Change Volume
16/10/26 €337.00 +0.15% 4,835
15/10/26 €336.50 +0.45% 7,702
14/10/26 €335.00 +3.08% 5,637
13/10/26 €325.00 +2.52% 6,812
12/10/26 €317.00 -0.16% 3,405
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Virbac
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
337.00EUR
Average target price
412.75EUR
Spread / Average Target
+22.48%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Virbac
  1. Stock Market
  2. Stocks
  3. VIRP Stock